• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.特发性膜性肾病肾病综合征自发缓解。
J Am Soc Nephrol. 2010 Apr;21(4):697-704. doi: 10.1681/ASN.2009080861. Epub 2010 Jan 28.
2
Factors affecting the long-term outcomes of idiopathic membranous nephropathy.影响特发性膜性肾病长期预后的因素。
BMC Nephrol. 2017 Mar 27;18(1):104. doi: 10.1186/s12882-017-0525-6.
3
Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.膜性肾病伴慢性肾功能不全的肾病综合征自发缓解。
Nephrol Dial Transplant. 2012 Jan;27(1):231-4. doi: 10.1093/ndt/gfr285. Epub 2011 May 30.
4
Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.膜性肾病患者蛋白尿完全缓解后的长期预后
Nephrol Dial Transplant. 1989;4(6):525-9.
5
Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.促肾上腺皮质激素凝胶治疗肾病综合征:一项多中心回顾性病例系列研究
BMC Nephrol. 2016 Mar 31;17:37. doi: 10.1186/s12882-016-0241-7.
6
Remission of proteinuria with treatment of Actinomyces infection: eradicating a cause of secondary membranous glomerulopathy suppresses nephrotic syndrome.放线菌感染治疗后蛋白尿缓解:根除继发性膜性肾小球病病因可抑制肾病综合征
Nephrol Dial Transplant. 2009 Oct;24(10):3236-9. doi: 10.1093/ndt/gfp284. Epub 2009 Jun 10.
7
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.一项关于确定促肾上腺皮质激素(H.P. Acthar® 凝胶)治疗特发性膜性肾病所致肾病综合征的剂量及疗效的初步研究。
Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8.
8
The natural history of the non-nephrotic membranous nephropathy patient.非肾病性膜性肾病患者的自然病程。
Clin J Am Soc Nephrol. 2009 Sep;4(9):1417-22. doi: 10.2215/CJN.01330209. Epub 2009 Aug 6.
9
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).原发性肾病综合征中蛋白尿缓解和复发、终末期肾病、死亡率以及主要结局的发生率:日本肾病综合征队列研究(JNSCS)。
Clin Exp Nephrol. 2020 Jun;24(6):526-540. doi: 10.1007/s10157-020-01864-1. Epub 2020 Mar 7.
10
Remissions and relapses in idiopathic membranous nephropathy.特发性膜性肾病的缓解与复发
Nephrol Dial Transplant. 1992;7 Suppl 1:85-90.

引用本文的文献

1
Identification of early predictors of clinical remission in primary membranous nephropathy: a analysis of the STARMEN trial.原发性膜性肾病临床缓解的早期预测因素识别:STARMEN试验分析
Clin Kidney J. 2025 Aug 13;18(9):sfaf256. doi: 10.1093/ckj/sfaf256. eCollection 2025 Sep.
2
Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective.从美国医疗保健角度看,Acthar®凝胶与标准治疗方案治疗成人特发性膜性肾病所致肾病综合征蛋白尿的每反应成本。
J Health Econ Outcomes Res. 2025 Aug 6;12(2):50-61. doi: 10.36469/001c.142078. eCollection 2025.
3
Clinical outcomes of immunosuppressive therapy in patients with seronegative anti-PLA2R antibodies and PLA2R-related membranous nephropathy.血清阴性抗PLA2R抗体及PLA2R相关膜性肾病患者免疫抑制治疗的临床结局
Clin Exp Nephrol. 2025 Jul 20. doi: 10.1007/s10157-025-02731-7.
4
Clinical Outcomes in the Nephrotic Syndrome Study Network: Disease Burden and Treatment Patterns over Time.肾病综合征研究网络的临床结局:疾病负担及随时间变化的治疗模式
Glomerular Dis. 2025 Jun 5;5(1):288-303. doi: 10.1159/000546655. eCollection 2025 Jan-Dec.
5
Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy.治疗时间对自身免疫性膜性肾病预后的影响
Kidney Int Rep. 2025 Apr 9;10(6):1907-1916. doi: 10.1016/j.ekir.2025.04.005. eCollection 2025 Jun.
6
Risk Factors for Disease Progression for Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN).治疗肾小球肾病网络(CureGN)中成人和儿童膜性肾病疾病进展的危险因素。
Kidney Int Rep. 2025 Mar 24;10(6):1917-1928. doi: 10.1016/j.ekir.2025.03.027. eCollection 2025 Jun.
7
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
8
Case report: Coexistence of optic neuritis and primary anti-PLA2R-positive membranous nephropathy.病例报告:视神经炎与原发性抗磷脂酶A2受体阳性膜性肾病并存
BMC Neurol. 2025 Mar 22;25(1):124. doi: 10.1186/s12883-025-04076-w.
9
Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment.探索适合中国医疗环境的利妥昔单抗治疗膜性肾病的策略。
BMC Nephrol. 2025 Jan 31;26(1):49. doi: 10.1186/s12882-025-03980-0.
10
Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy.羟氯喹作为膜性肾病患者附加治疗的初步试验
Kidney Int Rep. 2024 Sep 21;9(12):3446-3454. doi: 10.1016/j.ekir.2024.09.016. eCollection 2024 Dec.

本文引用的文献

1
The natural history of the non-nephrotic membranous nephropathy patient.非肾病性膜性肾病患者的自然病程。
Clin J Am Soc Nephrol. 2009 Sep;4(9):1417-22. doi: 10.2215/CJN.01330209. Epub 2009 Aug 6.
2
Idiopathic membranous nephropathy: diagnosis and treatment.特发性膜性肾病:诊断与治疗
Clin J Am Soc Nephrol. 2008 May;3(3):905-19. doi: 10.2215/CJN.04321007. Epub 2008 Jan 30.
3
A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.一项关于类固醇和环磷酰胺治疗特发性膜性肾病所致成人肾病综合征的随机对照试验。
J Am Soc Nephrol. 2007 Jun;18(6):1899-904. doi: 10.1681/ASN.2007020166. Epub 2007 May 9.
4
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.他克莫司单药治疗膜性肾病:一项随机对照试验。
Kidney Int. 2007 May;71(9):924-30. doi: 10.1038/sj.ki.5002215. Epub 2007 Mar 21.
5
Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study.霉酚酸酯“挽救治疗”抵抗性原发性肾小球肾炎的疗效与安全性——一项多中心研究
Nephrol Dial Transplant. 2007 May;22(5):1351-60. doi: 10.1093/ndt/gfl805. Epub 2007 Feb 20.
6
A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.一项比较甲基强的松龙加细胞毒性药物与合成促肾上腺皮质激素治疗特发性膜性肾病的随机试点试验。
Am J Kidney Dis. 2006 Feb;47(2):233-40. doi: 10.1053/j.ajkd.2005.10.016.
7
Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.特发性膜性肾病:治疗策略概述及理论依据
Am J Kidney Dis. 2005 Dec;46(6):1012-29. doi: 10.1053/j.ajkd.2005.08.020.
8
Management of membranous nephropathy: when and what for treatment.膜性肾病的管理:何时治疗及治疗目的
J Am Soc Nephrol. 2005 May;16(5):1188-94. doi: 10.1681/ASN.2005010028. Epub 2005 Mar 30.
9
The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum?特发性膜性肾病的治疗:难题还是困境?
Am J Kidney Dis. 2004 Sep;44(3):562-6.
10
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review.特发性膜性肾病的免疫抑制治疗:一项系统评价
Am J Kidney Dis. 2004 Sep;44(3):385-401.

特发性膜性肾病肾病综合征自发缓解。

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.

机构信息

Hospital 12 de Octubre, Madrid, Spain.

出版信息

J Am Soc Nephrol. 2010 Apr;21(4):697-704. doi: 10.1681/ASN.2009080861. Epub 2010 Jan 28.

DOI:10.1681/ASN.2009080861
PMID:20110379
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2844306/
Abstract

Spontaneous remission is a well known characteristic of idiopathic membranous nephropathy, but contemporary studies describing predictors of remission and long-term outcomes are lacking. We conducted a retrospective, multicenter cohort study of 328 patients with nephrotic syndrome resulting from idiopathic membranous nephropathy that initially received conservative therapy. Spontaneous remission occurred in 104 (32%) patients: proteinuria progressively declined after diagnosis until remission of disease at 14.7 +/- 11.4 months. Although spontaneous remission was more frequent with lower levels of baseline proteinuria, it also frequently occurred in patients with massive proteinuria: 26% among those with baseline proteinuria 8 to 12 g/24 h and 22% among those with proteinuria >12 g/24 h. Baseline serum creatinine and proteinuria, treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, and a >50% decline of proteinuria from baseline during the first year of follow-up were significant independent predictors for spontaneous remission. Only six patients (5.7%) experienced a relapse of nephrotic syndrome. The incidence of death and ESRD were significantly lower among patients with spontaneous remission. In conclusion, spontaneous remission is common among patients with nephrotic syndrome resulting from membranous nephropathy and carries a favorable long-term outcome with a low incidence of relapse. A decrease in proteinuria >50% from baseline during the first year predicts spontaneous remission.

摘要

自发缓解是特发性膜性肾病的一个显著特征,但目前缺乏描述缓解预测因素和长期结果的当代研究。我们对 328 例接受保守治疗的特发性膜性肾病肾病综合征患者进行了回顾性、多中心队列研究。104 例(32%)患者出现自发缓解:蛋白尿在诊断后逐渐下降,直至 14.7±11.4 个月时疾病缓解。尽管自发缓解在基线蛋白尿水平较低时更为常见,但在大量蛋白尿患者中也经常发生:基线蛋白尿为 8-12g/24h 的患者中占 26%,蛋白尿>12g/24h 的患者中占 22%。基线血清肌酐和蛋白尿、血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂的治疗以及第一年随访期间蛋白尿较基线下降>50%是自发缓解的显著独立预测因素。仅有 6 例患者(5.7%)出现肾病综合征复发。自发缓解患者的死亡率和 ESRD 发生率显著较低。总之,膜性肾病肾病综合征患者自发缓解较为常见,长期预后良好,复发率低。第一年蛋白尿较基线下降>50%可预测自发缓解。